Sign in

Doug Miehm

Managing Director and Senior Healthcare Analyst at RBC Capital Markets

Doug Miehm is a Managing Director and Senior Healthcare Analyst at RBC Capital Markets, specializing in equity research on biotechnology, pharmaceuticals, and healthcare services. He covers companies such as Bausch Health Companies, Aurinia Pharmaceuticals, WELL Health Technologies, Correvio Pharma, Novadaq, Liminal BioSciences, and others, with a performance record including a 47% success rate and an average return of 1.4% per rating based on TipRanks, and a documented best call yielding +286.9% on Opsens Inc. Since joining RBC Capital Markets, Miehm has published over 500 equity recommendations and has been recognized as a TopGun Healthcare Analyst by Brendan Wood International. He holds key professional credentials and securities licenses, is frequently featured at major conferences, and is noted for his expertise in market-leading healthcare research.

Doug Miehm's questions to Bausch & Lomb (BLCO) leadership

Question · Q3 2025

Doug Miehm asked about the potential for MIEBO's profitability timeline to shift earlier than 2026, given its recent strong performance. He also inquired about the company's capital allocation strategy as it becomes more successful, specifically regarding debt paydown versus reinvestment in the business.

Answer

CFO and EVP Sam Eldessouky explained that MIEBO is transitioning from a launch to a growth phase, with deliberate, high-ROI investments contributing to overall P&L leverage and margin expansion, with more details for 2026 to be shared at Investor Day. Chairman and CEO Brent Saunders and Sam Eldessouky emphasized that deleveraging to achieve investment grade is a high priority, alongside opportunistic tuck-in M&A and R&D investments, all aimed at increasing shareholder value.

Ask follow-up questions

Question · Q3 2025

Doug Miehm inquired about the potential for MIEBO's profitability timeline to shift earlier than the guided 2026, given its recent strength, and asked about the company's capital allocation strategy for incremental cash over the next one to two years, specifically regarding debt paydown versus reinvestment.

Answer

CFO and EVP Sam Eldessouky explained that MIEBO is transitioning from a launch to a growth phase, and while investments will continue, they will be deliberate, with more details on 2026 profitability to be shared at Investor Day. Regarding capital allocation, Chairman and CEO Brent Saunders emphasized a strong commitment to deleveraging through EBITDA growth and debt paydown, while also seeking smaller, profitable tuck-in M&A and investing in R&D/IP, with lowering debt ratios being a high priority.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts